# Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

> **NCT00056524** · PHASE3 · COMPLETED · sponsor: **Avanir Pharmaceuticals** · enrollment: 600 (estimated)

## Conditions studied

- Alzheimer's Disease
- Stroke
- Parkinson's Disease
- Traumatic Brain Injury

## Interventions

- **DRUG:** AVP-923

## Key facts

- **NCT ID:** NCT00056524
- **Lead sponsor:** Avanir Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2016-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056524, "Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00056524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*